Cannabis and Psychosis: New Study Shows No Significant Link

A new study concludes that there is no significant link between cannabis consumption and the onset of psychosis, which contrasts with some previous data and other categorical statements.

For more of the latest research findings, along with all the latest in lifestyle and legalization, download our free cannabis news app. 

Details of the Study and Results

The researchers examined the association between cannabis consumption and the incidence of psychotic disorders in individuals with a high clinical risk of psychosis.

Current and past cannabis consumption was assessed in more than 300 people considered to be at “high clinical risk of psychosis” and 67 healthy participants.

All participants were followed for two years from the start of the study, during which they were evaluated using the Global Assessment of Functioning disability scale. The transition to psychosis and the persistence of psychotic symptoms were evaluated using the Comprehensive Assessment of At-Risk Mental States criteria.

According to the results, 16.2% of the high-risk clinical sample developed psychosis during the follow-up. Among those who did not become psychotic, 51.4% had persistent symptoms, and 48.6% were in remission.

The authors state: “There was no significant association between a measure of cannabis consumption at baseline and transition to psychosis, persistence of symptoms, or functional outcome.”

“These results contrast with epidemiological data suggesting that cannabis consumption increases the risk of psychotic disorders.”

Previous Research on Cannabis and Psychosis

Factors such as THC potency, frequency of consumption, age, loneliness, or the consumer’s genetic background can all contribute to the risk of developing psychosis. Experts generally advise caution in cannabis consumption for anyone with a family history of psychosis or who may be predisposed to developing symptoms.

However, despite the lack of conclusive evidence, concerns about the risks of psychosis are often used by opponents as an argument against drug policy reform, particularly regarding cannabis.

No Difference in Psychosis Rates Between Jurisdictions

In an article published earlier this year, researchers at the University of Pennsylvania Hospital in Philadelphia examined commercial claims and Medicare Advantage data from more than 63 million people between 2003 and 2017.

They did not find a “statistically significant difference” in rates of psychosis-related diagnoses or antipsychotics prescribed in states with medical or recreational cannabis policies compared to those where the plant is still prohibited.

No Dose-Dependent Link Between Psychosis and Cannabis

In addition, a 2021 study examined the relationship between cannabis consumption in adolescents and psychoses that occurred in adulthood in a longitudinal twin-control analysis.

They did not identify any dose-response relationship in models that compared the twin who consumed the most cannabis to the other who consumed less in relation to the predisposition to psychosis in adulthood.

The researchers also indicated that there were no potentially different effects on the twins’ levels of cannabis exposure and the risk of developing psychosis later in life.

—

(Featured image by Pavel Danilyuk via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.